Gastritis classification: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(7 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Gastritis}}
{{Gastritis}}
{{CMG}}; {{AE}} {{ARK}}}}
{{CMG}}; {{AE}} {{ARK}}<nowiki>}}</nowiki>


==Overview==
==Overview==
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping.
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting [[gastric]] histology. Gastritis staging combines the [[atrophy]] score which is determined by biopsy and the [[atrophy]] topography which is determined by directed [[biopsy]] mapping.


==Classification==
==Classification==
*The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. <ref name="pmid8827022">{{cite journal| author=Dixon MF, Genta RM, Yardley JH, Correa P| title=Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. | journal=Am J Surg Pathol | year= 1996 | volume= 20 | issue= 10 | pages= 1161-81 | pmid=8827022 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8827022  }} </ref>
*The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. <ref name="pmid8827022">{{cite journal| author=Dixon MF, Genta RM, Yardley JH, Correa P| title=Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. | journal=Am J Surg Pathol | year= 1996 | volume= 20 | issue= 10 | pages= 1161-81 | pmid=8827022 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8827022  }} </ref><br />
<br/>
{|
{|
!colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Classification and grading of Gastritis: Updated Sydney System'''
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Classification and grading of Gastritis: Updated Sydney System'''
|-
|-
!colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + | Type of Gastritis
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + | Type of Gastritis
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Etiology
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Etiology
!style="background:#4479BA; color: #FFFFFF;" align="center" + |Gastritis synonyms
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Gastritis synonyms
|-
|-
|colspan="2" style="background:#DCDCDC;" align="center" + | Non-atrophic
| colspan="2" style="background:#DCDCDC;" align="center" + | '''Non-atrophic'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Helicobacter pylori
*''[[Helicobacter pylori]]''
*Other factors
*Other factors
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Superficial
*Superficial
*Diffuse antral gastritis (DAG)
*Diffuse antral gastritis (DAG)
Line 28: Line 27:
*Type B*
*Type B*
|-
|-
|rowspan="4" style="background:#DCDCDC;" align="center" + |Atrophic
| rowspan="4" style="background:#DCDCDC;" align="center" + |'''Atrophic'''
| style="background:#DCDCDC;" align="center" + |Autoimmune
| style="background:#DCDCDC;" align="center" + |'''Autoimmune'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Autoimmunity
*[[Autoimmunity]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Type A*
*Type A*
*Diffuse corporal
*Diffuse corporal
*Pernicious anemia-associated
*[[Pernicious anemia]]-associated
|-
|-
|rowspan="3" style="background:#DCDCDC;" align="center" + |Multifocal atrophic
| rowspan="3" style="background:#DCDCDC;" align="center" + |'''Multifocal atrophic'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Helicobacter pylori
*''[[Helicobacter pylori]]''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Type B*, type AB*
*Type B*, type AB*
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Dietary
*Dietary
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Environmental
*Environmental
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Environmental factors
*Environmental factors
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Metaplastic
*Metaplastic
|-
|-
|rowspan="21" style="background:#DCDCDC;" align="center" + | Special forms
| rowspan="21" style="background:#DCDCDC;" align="center" + | '''Special forms'''
|rowspan="4" style="background:#DCDCDC;" align="center" + | Chemical
| rowspan="4" style="background:#DCDCDC;" align="center" + | '''Chemical'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Chemical irritation
*Chemical irritation
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Reactive
*Reactive
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Bile
*[[Bile]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Reflux
*Reflux
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*NSAIDs
*[[NSAIDs]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*NSAID
*[[NSAID]]
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Other agents
*Other agents
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Type C
*Type C
|-
|-
| style="background:#DCDCDC;" align="center" + |Radiation
| style="background:#DCDCDC;" align="center" + |'''Radiation'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Radiation injury
*[[Radiation injury]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|-
|-
| rowspan="4" style="background:#DCDCDC;" align="center" + |Lymphocytic
| rowspan="4" style="background:#DCDCDC;" align="center" + |'''Lymphocytic'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Idiopathic? Immune mechanisms
*Idiopathic? [[Immune]] mechanisms
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Varioliform (endoscopic)
*Varioliform ([[endoscopic]])
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Gluten
*[[Gluten]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Celiac disease-associated
*[[Celiac disease]]-associated
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Drug (ticlopidine)
*Drug ([[ticlopidine]])
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*H. pylori
*''[[Helicobacter pylori]]''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|-
|-
| rowspan="5" style="background:#DCDCDC;" align="center" + |Noninfectious granulomatous
| rowspan="5" style="background:#DCDCDC;" align="center" + |'''Noninfectious granulomatous'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Crohn's disease
*[[Crohn's disease]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Sarcoidosis
*[[Sarcoidosis]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Granulomatosis with polyangiitis and other vasculitides
*[[Granulomatosis with polyangiitis]] and other [[vasculitides]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Foreign substances
*Foreign substances
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Idiopathic
*Idiopathic
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Isolated granulomatous
*Isolated [[granulomatous]]
|-
|-
| rowspan="2" style="background:#DCDCDC;" align="center" + |Eosinophilic
| rowspan="2" style="background:#DCDCDC;" align="center" + |'''Eosinophilic'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Food sensitivity
*[[Food allergy|Food sensitivity]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Allergic
*[[Allergic]]
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Other allergies
*Other [[allergies]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|-
|-
| rowspan="2" style="background:#DCDCDC;" align="center" + |Other infectious gastritides
| rowspan="2" style="background:#DCDCDC;" align="center" + |'''Other infectious gastritides'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Bacteria (other than H. pylori)
*[[Bacteria]] (other than ''[[Helicobacter pylori]]'')
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Phlegmonous
*Phlegmonous
|-
|-
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Viruses
*[[Viruses]]
*Fungi
*[[Fungi]]
*Parasites
*[[Parasites]]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
|}
|}
<br/>
<br />
<br/>
<br />
*In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. <ref name="pmid17142647">{{cite journal| author=Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G et al.| title=Gastritis staging in clinical practice: the OLGA staging system. | journal=Gut | year= 2007 | volume= 56 | issue= 5 | pages= 631-6 | pmid=17142647 | doi=10.1136/gut.2006.106666 | pmc=1942143 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17142647  }} </ref> <ref name="pmid18424244">{{cite journal| author=Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K et al.| title=OLGA staging for gastritis: a tutorial. | journal=Dig Liver Dis | year= 2008 | volume= 40 | issue= 8 | pages= 650-8 | pmid=18424244 | doi=10.1016/j.dld.2008.02.030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18424244  }} </ref>
*In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. <ref name="pmid17142647">{{cite journal| author=Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G et al.| title=Gastritis staging in clinical practice: the OLGA staging system. | journal=Gut | year= 2007 | volume= 56 | issue= 5 | pages= 631-6 | pmid=17142647 | doi=10.1136/gut.2006.106666 | pmc=1942143 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17142647  }} </ref> <ref name="pmid18424244">{{cite journal| author=Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K et al.| title=OLGA staging for gastritis: a tutorial. | journal=Dig Liver Dis | year= 2008 | volume= 40 | issue= 8 | pages= 650-8 | pmid=18424244 | doi=10.1016/j.dld.2008.02.030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18424244  }} </ref>
<br/>
<br />
{|
{|
!colspan="6" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Gastritis staging in clinical practice: The OLGA staging system'''
! colspan="6" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Gastritis staging in clinical practice: The OLGA staging system'''
|-
|-
! rowspan="2" colspan="2" style="background:#4479BA; color: #FFFFFF;" + | '''Atrophy Score'''
! colspan="2" rowspan="2" style="background:#4479BA; color: #FFFFFF;" + | '''Atrophy Score'''
! colspan="4" style="background:#4479BA; color: #FFFFFF;" + |  '''Corpus'''
! colspan="4" style="background:#4479BA; color: #FFFFFF;" + |  '''Corpus'''
|-
|-
! style="background:#DCDCDC; + | No Atrophy (Score: 0)
! style="background:#DCDCDC;" align="center" + | No Atrophy (Score: 0)
! style="background:#DCDCDC; + | Mild Atrophy (Score: 1)
! style="background:#DCDCDC;" align="center" + | Mild Atrophy (Score: 1)
! style="background:#DCDCDC; + | Moderate Atrophy (Score: 2)
! style="background:#DCDCDC;" align="center" + | Moderate Atrophy (Score: 2)
! style="background:#DCDCDC; + | Severe Atrophy (Score: 3)
! style="background:#DCDCDC;" align="center" + | Severe Atrophy (Score: 3)
|-
|-
!rowspan="4" style="background:#7d7d7d; color: #FFFFFF;" + |
! rowspan="4" style="background:#7d7d7d; color: #FFFFFF;" align="center" + |
A
A


Line 171: Line 170:
M
M


! style="background:#DCDCDC; + | No Atrophy (Score: 0) (''including incisura angularis'')
! style="background:#DCDCDC;" align="center" + | No Atrophy (Score: 0) (''including incisura angularis'')
| STAGE 0
| style="background:#F5F5F5;" align="center" + | STAGE 0
| STAGE I
| style="background:#F5F5F5;" align="center" + | STAGE I
| STAGE II
| style="background:#F5F5F5;" align="center" + | STAGE II
| STAGE II
| style="background:#F5F5F5;" align="center" + | STAGE II
|-
|-
! style="background:#DCDCDC; + | Mild Atrophy (Score: 1)  (''including incisura angularis'')
! style="background:#DCDCDC;" align="center" + | Mild Atrophy (Score: 1)  (''including incisura angularis'')
 
| style="background:#F5F5F5;" align="center" + | STAGE I
| STAGE I
| style="background:#F5F5F5;" align="center" + | STAGE I
| STAGE I
| style="background:#F5F5F5;" align="center" + | STAGE II
| STAGE II
| style="background:#F5F5F5;" align="center" + | STAGE III
| STAGE III
|-
|-
! style="background:#DCDCDC; + | Moderate Atrophy (Score: 2)  (''including incisura angularis'')
! style="background:#DCDCDC;" align="center" + | Moderate Atrophy (Score: 2)  (''including incisura angularis'')
 
| style="background:#F5F5F5;" align="center" + | STAGE II
| STAGE II
| style="background:#F5F5F5;" align="center" + | STAGE II
| STAGE II
| style="background:#F5F5F5;" align="center" + | STAGE III
| STAGE III
| style="background:#F5F5F5;" align="center" + | STAGE IV
| STAGE IV
|-
|-
! style="background:#DCDCDC; + | Severe Atrophy (Score: 3)  (''including incisura angularis'')
! style="background:#DCDCDC;" align="center" + | Severe Atrophy (Score: 3)  (''including incisura angularis'')
 
| style="background:#F5F5F5;" align="center" + | STAGE III
| STAGE III
| style="background:#F5F5F5;" align="center" + | STAGE III
| STAGE III
| style="background:#F5F5F5;" align="center" + | STAGE IV
| STAGE IV
| style="background:#F5F5F5;" align="center" + | STAGE IV
| STAGE IV
|}
|}


Line 202: Line 198:


{|
{|
!colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Sydney system for grading of Chronic Gastritis'''
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Sydney system for grading of Chronic Gastritis'''
|-
|-
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Feature
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Feature
Line 208: Line 204:
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Grading guidelines
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Grading guidelines
|-
|-
| style="background:#DCDCDC; + | Chronic inflammation
| style="background:#DCDCDC; + " | '''Chronic inflammation'''
| style="background:#F5F5F5; + |  
| style="background:#F5F5F5; + " |  
*Increased [[lymphocytes]] and [[plasma cells]] in [[lamina propria]]
*Increased [[lymphocytes]] and [[plasma cells]] in [[lamina propria]]
| style="background:#F5F5F5; + |  
| style="background:#F5F5F5; + " |  
* Mild, moderate or severe increase in density
* Mild, moderate or severe increase in density
|-
|-
| style="background:#DCDCDC; + | Activity
| style="background:#DCDCDC; + " | '''Activity'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*[[Neutrophil|Neutrophilic]] infiltrates of the [[lamina propria]], pits or surface [[epithelium]]
*[[Neutrophil|Neutrophilic]] infiltrates of the [[lamina propria]], pits or surface [[epithelium]]
| style="background:#F5F5F5; + |  
| style="background:#F5F5F5; + " |  
* Mild: less than one-third of pits and surface infiltrated
* Mild: less than one-third of pits and surface infiltrated
* Moderate: one-third to two-thirds
* Moderate: one-third to two-thirds
* Severe: more than two-thirds
* Severe: more than two-thirds
|-
|-
| style="background:#DCDCDC; + | [[Atrophy]]
| style="background:#DCDCDC; + " | [[Atrophy|'''Atrophy''']]
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Loss of specialized glands from either antrum or corpus
*Loss of specialized glands from either [[antrum]] or corpus
| style="background:#F5F5F5; + |  
| style="background:#F5F5F5; + " |  
* Mild, moderate, or severe loss
* Mild, moderate, or severe loss
|-
|-
| style="background:#DCDCDC; + | ''[[Helicobacter pylori]]''
| style="background:#DCDCDC; + " | ''[[Helicobacter pylori|'''Helicobacter pylori''']]''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*''[[H. pylori]]'' density
*''[[H. pylori]]'' density
| style="background:#F5F5F5; + |  
| style="background:#F5F5F5; + " |  
* Mild colonization: scattered organisms covering less than one-third of the surface
* Mild colonization: scattered organisms covering less than one-third of the surface
* Moderate colonization: intermediate numbers  
* Moderate colonization: intermediate numbers  
* Severe colonization: large clusters or a continuous layer over two-thirds of surface
* Severe colonization: large clusters or a continuous layer over two-thirds of surface
|-
|-
| style="background:#DCDCDC; + | Intestinal [[Metaplasia]]
| style="background:#DCDCDC; + " | '''Intestinal [[Metaplasia]]'''
| style="background:#F5F5F5; + |
| style="background:#F5F5F5; + " |
*Intestinal [[metaplasia]] of the epithelium
*[[Intestinal]] [[metaplasia]] of the epithelium
| style="background:#F5F5F5; + |  
| style="background:#F5F5F5; + " |  
* Mild: less than one-third of mucosa involved
* Mild: less than one-third of mucosa involved
* Moderate: one-third to two-thirds  
* Moderate: one-third to two-thirds  
Line 248: Line 244:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Needs content]]
[[Category:Gastroenterology]]
 
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Medicine]]
[[Category:Gastroenterology]]
[[Category:Up-To-Date]]

Latest revision as of 21:49, 29 July 2020

Gastritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gastritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Diagnostic tests

Endoscopic tests
Nonendoscopic tests

X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastritis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastritis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastritis classification

CDC on Gastritis classification

Gastritis classification in the news

Blogs on Gastritis classification

Directions to Hospitals Treating Gastritis

Risk calculators and risk factors for Gastritis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]}}

Overview

The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping.

Classification

  • The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. [1]
Classification and grading of Gastritis: Updated Sydney System
Type of Gastritis Etiology Gastritis synonyms
Non-atrophic
  • Superficial
  • Diffuse antral gastritis (DAG)
  • Chronic antral gastritis (CAG)
  • Interstitial - follicular
  • Hypersecretory
  • Type B*
Atrophic Autoimmune
Multifocal atrophic
  • Type B*, type AB*
  • Dietary
  • Environmental
  • Environmental factors
  • Metaplastic
Special forms Chemical
  • Chemical irritation
  • Reactive
  • Reflux
  • Other agents
  • Type C
Radiation
Lymphocytic
Noninfectious granulomatous
  • Foreign substances
  • Idiopathic
Eosinophilic
Other infectious gastritides
  • Phlegmonous



  • In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. [2] [3]


Gastritis staging in clinical practice: The OLGA staging system
Atrophy Score Corpus
No Atrophy (Score: 0) Mild Atrophy (Score: 1) Moderate Atrophy (Score: 2) Severe Atrophy (Score: 3)

A

N

T

R

U

M

No Atrophy (Score: 0) (including incisura angularis) STAGE 0 STAGE I STAGE II STAGE II
Mild Atrophy (Score: 1) (including incisura angularis) STAGE I STAGE I STAGE II STAGE III
Moderate Atrophy (Score: 2) (including incisura angularis) STAGE II STAGE II STAGE III STAGE IV
Severe Atrophy (Score: 3) (including incisura angularis) STAGE III STAGE III STAGE IV STAGE IV

Sydney system for grading of chronic gastritis[1]

Sydney system for grading of Chronic Gastritis
Feature Definition Grading guidelines
Chronic inflammation
  • Mild, moderate or severe increase in density
Activity
  • Mild: less than one-third of pits and surface infiltrated
  • Moderate: one-third to two-thirds
  • Severe: more than two-thirds
Atrophy
  • Loss of specialized glands from either antrum or corpus
  • Mild, moderate, or severe loss
Helicobacter pylori
  • Mild colonization: scattered organisms covering less than one-third of the surface
  • Moderate colonization: intermediate numbers
  • Severe colonization: large clusters or a continuous layer over two-thirds of surface
Intestinal Metaplasia
  • Mild: less than one-third of mucosa involved
  • Moderate: one-third to two-thirds
  • Severe: more than two-thirds

References

  1. 1.0 1.1 Dixon MF, Genta RM, Yardley JH, Correa P (1996). "Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994". Am J Surg Pathol. 20 (10): 1161–81. PMID 8827022.
  2. Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G; et al. (2007). "Gastritis staging in clinical practice: the OLGA staging system". Gut. 56 (5): 631–6. doi:10.1136/gut.2006.106666. PMC 1942143. PMID 17142647.
  3. Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K; et al. (2008). "OLGA staging for gastritis: a tutorial". Dig Liver Dis. 40 (8): 650–8. doi:10.1016/j.dld.2008.02.030. PMID 18424244.

Template:WH Template:WS